Chikungunya virus vaccine prepared by Tween-ether extraction

Area of Science:

• Virology
• Vaccine Development
• Immunology

Background:

• Chikungunya virus (CHIKV) poses a significant global health threat, necessitating effective vaccine strategies.
• Traditional inactivation methods like formalin may impact vaccine antigenicity.
• Exploring alternative inactivation methods is crucial for developing potent CHIKV vaccines.

Purpose of the Study:

• To evaluate the immunogenicity and protective efficacy of Chikungunya virus vaccines prepared using Tween 80 and ether inactivation.
• To characterize the physical and antigenic properties of Tween-ether treated CHIKV.
• To determine optimal conditions for Tween-ether inactivation preserving CHIKV hemagglutinin and immunogenicity.

Main Methods:

• Chikungunya virus grown in green monkey kidney cell cultures was inactivated using Tween 80 and ether.
• Vaccine immunogenicity was assessed by measuring hemagglutination-inhibiting, complement-fixing, and neutralizing antibodies in mice.
• Protective efficacy was evaluated through challenge studies with live virus.
• Physical characteristics of the inactivated virus were analyzed using sucrose and cesium chloride density gradient centrifugation.

Main Results:

• Tween-ether inactivated CHIKV vaccines demonstrated comparable immunogenicity to formalin-inactivated vaccines.
• Both vaccine types induced robust antibody responses and protected mice against live CHIKV challenge.
• Tween-ether treatment inactivated the virus, increased hemagglutinin titer, and altered particle characteristics (smaller, denser), likely due to lipid removal.
• Optimized Tween-ether treatment conditions preserved high hemagglutinin titers and vaccine immunogenicity.

Conclusions:

• Tween 80 and ether inactivation is a viable method for producing immunogenic and protective Chikungunya virus vaccines.
• This inactivation process enhances viral hemagglutinin and reduces infectivity, offering a potentially superior alternative to formalin.
• The findings support the development of Tween-ether inactivated CHIKV vaccines with preserved immunogenicity and enhanced antigen presentation.